Circassia is a world class specialty pharmaceutical business focused on respiratory disease.
Circassia has a growing commercial organisation to promote its innovative asthma management products directly to specialist physicians. It markets the COPD product Tudorza® in the US and has a pipeline of asthma and COPD treatments in development.
The acquisition of Prosonix has provided Circassia with a broad pipeline of respiratory products. Circassia’s lead asthma product targets substitution of GSK’s Flixotide® pMDI, and was recently approved in the UK. Circassia expects two further filings for regulatory approval by the end of 2017, for products targeting direct substitution of Serevent® pMDI and Seretide® pMDI. The company is also developing a number of novel treatments for COPD.
Circassia was established in 2006, and in March 2014 it completed an initial public offering on the London Stock Exchange. In June 2015, it completed the acquisitions of Aerocrine and Prosonix as part of its strategy to independently commercialise its products and broaden its pipeline, and in April 2017 it established a US commercial collaboration with AstraZeneca through which it acquired the commercial rights to Duaklir®, which has passed phase III clinical trial in the US.